A2B-543

N/A

Report date: 2026/04/02 17:22:41

Base Information

Drug NameA2B-543
Drug Alias NameA2B543
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Mesothelin
TargetsMesothelin
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesA2 Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesA2 Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A